Mentored by Dr Vivek Singh and Dr Muralidhar Ramappa, Salman’s research is focused on on identifying pathogenic SLC4A11 variants in CHED and utilizes CRISPR-based genome editing to generate in vitro knockout and knock-in models, enhancing understanding of corneal endothelial dysfunction and contributing to the development of targeted therapeutic strategies for ocular genetic disorders.
Why the study matters: This study advances understanding of CHED pathogenesis by identifying novel SLC4A11 variants and establishing CRISPR-based cellular models, providing a foundation for developing safe and effective ocular gene therapies.
'The integrative approach of clinical genetics with advanced gene-editing technologies holds great potential to generate alternative therapeutics, advancing precision medicine in ocular gene therapy.'
